Mega Genomics Limited (6667) Price & Analysis

Mega Genomics Limited is a genetic testing provider based in China, specializing in both direct-to-consumer genetic assessments and comprehensive cancer screening solutions. The company's diverse portfolio includes general health evaluations, such as an ApoE gene analysis to gauge lipid metabolism and an individual's susceptibility to conditions like Alzheimer's disease. It also assesses folate metabolism to identify risks for hyperhomocysteinemia, as well as various cardiovascular and cerebrovascular disorders. Additional general offerings cover Parkinson's disease risk, extensive cancer risk profiling, and specific cardiovascular/cerebrovascular disease risk assessments. Furthermore, Mega Genomics delivers advanced diagnostic tests, including genetic screening for hereditary breast and ovarian cancers, alongside specialized tests for colorectal and gastric cancer detection utilizing Septin9 and RNF180/Septin9 markers, respectively. For premium clientele, executive testing options encompass personal whole-genome sequencing and whole-exome sequencing packages for adults. The company employs a combination of proprietary laboratory-developed tests (LDTs) and in-vitro diagnostic (IVD) kits to conduct its array of services. Its clientele primarily consists of health examination centers, hospitals, and a broad range of other institutional and individual clients. Established in Beijing, China, in 2016, Mega Genomics Limited operates from its headquarters there.